Current Report Filing (8-k)
14 12월 2012 - 8:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): December 13, 2012
VANDA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-34186
|
|
03-0491827
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
|
|
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC
|
|
20037
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (202) 734-3400
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events
On December 13, 2012, Vanda Pharmaceuticals Inc. issued a press release announcing that the European Medicines Agencys Committee for Medicinal Product for Human Use had issued a negative
opinion recommending against approval of Fanaptum (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated by
reference herein.
Item 9.01 Financial Statements and Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of Vanda Pharmaceuticals Inc. dated December 13, 2012.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
VANDA PHARMACEUTICALS INC.
|
|
|
By:
|
|
/s/ J
AMES
P. K
ELLY
|
|
|
Name:
|
|
James P. Kelly
|
|
|
Title:
|
|
Senior Vice President, Chief Financial Officer, Secretary, and Treasurer
|
Dated: December 13, 2012
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024